AtriCure Inc - Company Profile
Powered by 
All the sales intelligence you need on AtriCure Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AtriCure Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AtriCure Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
AtriCure Inc (AtriCure) is a company specialising in the development and provision of medical technologies for the treatment of atrial fibrillation (Afib) and related conditions. The company's primary activities involve the development and distribution of medical devices used by electrophysiologists and cardiothoracic surgeons. AtriCure's major products include Isolator clamps, ablation pens, hardware generators, Cryoice probes, EPi-Sense systems, EPi-Ease access devices, Lumitip tools, AtriClip exclusion systems, cryoSPHERE nerve block probes, and minimally invasive surgical instruments like retractors, graspers, and scissors. Its products are used in various surgical procedures, including open-heart and minimally invasive surgeries, to treat Afib and manage post-operative pain. The company markets its products through various brands such as AtriCure, Isolator, Synergy, Lariat, Hybrid AF, cryosphere, cryoICE, AtriClip, and EPi-Sense. It operates in the US, Germany, France, the UK, the Benelux region, Canada, and Australia, among other locations. AtriCure Inc is headquartered in Mason, Ohio, the US.
Headquarters
United States of America
Address
7555 Innovation Way, Mason, Ohio, 45040
Website
https://www.atricure.com/
Telephone
1 513 7554100
No of Employees
1,350
Industry
Medical Equipment
Ticker Symbol & Exchange
ATRC (NASD)
Revenue (2024)
$534.5M
14.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
74.4%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
77.7%
(2024 vs 2023)
* As of and is in US$
AtriCure Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Concomitant Surgical Ablation Therapy: | AtriCure |
| Isolator Synergy Clamps | Coolrail |
| Ablation Sensing Unit and Switch Matrix | Isolator |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In September, the company introduced cryoXT Device for Post-Operative Pain Management Following Amputation. |
| 2024 | New Products/Services | In October, the company introduced the cryoSPHERE MAX cryoablation probe. |
| 2024 | New Products/Services | In April, the company launched the cryoSPHERE+ cryoablation probe for post-operative pain management. |
Competitor Comparison
| Key Parameters | AtriCure Inc | Medtronic Plc | Boston Scientific Corp | Merit Medical Systems Inc | Biosense Webster Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Ireland | United States of America | United States of America | United States of America |
| City | Mason | Dublin | Marlborough | South Jordan | Irvine |
| State/Province | Ohio | - | Massachusetts | Utah | California |
| No. of Employees | 1,350 | 95,000 | 59,000 | 7,500 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert S. White | Chairman | Executive Board | 2013 | 64 |
| Michael H. Carrel | President; Director; Chief Executive Officer | Executive Board | 2012 | 55 |
| Angela L. Wirick | Chief Financial Officer | Senior Management | 2020 | 48 |
| Douglas J. Seith | Chief Operating Officer | Senior Management | 2015 | 58 |
| Justin J. Noznesky | Chief Marketing Officer; Chief Strategy Officer | Senior Management | 2021 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer